Pacira BioSciences, Inc.

PCRX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001396814

B/C

on the B/C boundary of 369 graded peers in healthcare

rank 148 of 369; percentile 39.9; sampling error 2.5 points; lower is stronger



B/C, the elk



Scoreboard	
Profitability	C percentile 46.8
Solvency	B percentile 33.2
Growth and financing	C percentile 56.3
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.3B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	11 of 14
Graded from	filings received through Feb 26, 2026 259 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$36.46 2026-11-11; market equity $1.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the "Skyepharma Acquisition").

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.8						
Gross profitability	45.6%	32.3%		27.2	365	2025-12-31
Return on invested capital	0.8%	9.3%		72.6	74	2025-12-31
Accruals ratio	(10.3%)	(6.6%)		40.5	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five consecutive annual gross margins are required						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 33.2						
Twelve-month failure probability	0.03%	0.08%	15.4	247	2026-09-30	
Altman Z double-prime	3.08	(0.35)	24.6	745	2025-12-31	
Net debt to EBITDA	1.94x	1.82x	52.7	75	2025-12-31	
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.54x	2.95x	40.1	827	2025-12-31	
Growth and financing, sleeve percentile 56.3						
Revenue growth, three-year compound	not computable	10.1%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	5.9%	11.0%	57.4	95	2025-12-31	
Reinvestment rate	(1,044.0%)	37.1%	99.0	105	2025-12-31	
Asset growth, three years	(9.0%)	2.2%	67.9	695	2025-12-31	
Net share issuance, one year	(12.5%)	2.5%	0.8	628	2026-02-23	

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
143	Lakeland Industries Inc. (LAKE)	38.6	B/C	late filer, fortress balance sheet
144	LifeStance Health Group, Inc. (LFST)	38.9	B/C	
145	CorMedix Inc. (CRMD)	39.1	B/C	
146	National Healthcare Corp. (NHC)	39.4	B/C	fortress balance sheet
147	Celldex Therapeutics, Inc. (CLDX)	39.7	B/C	short runway
148	Pacira BioSciences, Inc. (PCRX)	39.9	B/C	
149	Myomo, Inc. (MYO)	40.2	B/C	fortress balance sheet
150	Lifevantage Corp. (LFVN)	40.5	B/C	
151	Medtronic plc (MDT)	40.8	B/C	
152	Community Health Systems Inc. (CYH)	41.0	B/C	
153	Xeris Biopharma Holdings, Inc. (XERS)	41.3	B/C	

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	17.2%	(1.9%)	60
Distance from 52-week high	(0.08%)	(27.8%)	93
EBIT to enterprise value	1.3%	(1.6%)	59
Free cash flow yield	9.3%	(1.0%)	90
Book value to price	0.49	0.27	68
Sales to price	0.50	0.29	66
Composite equity issuance, five years	(9.0%)	20.8%	16
Relative strength against the sector, log excess return	(0.01)	(0.19)	60

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$247.0M
Operating cash flow, four quarters	$176.9M
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$16.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$726.4M	2025-12-31	2026-02-26	10-K	26-012297
2	cost of revenue	us-gaap:CostOfRevenue	$149.7M	2025-12-31	2026-02-26	10-K	26-012297
3	assets	us-gaap:Assets	$1.3B	2025-12-31	2026-02-26	10-K	26-012297
4	operating income	us-gaap:OperatingIncomeLoss	$19.2M	2025-12-31	2026-02-26	10-K	26-012297
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$16.9M	2025-12-31	2026-02-26	10-K	26-012297
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$9.8M	2025-12-31	2026-02-26	10-K	26-012297
7	total debt	us-gaap:LongTermDebt	$372.2M	2025-12-31	2026-02-26	10-K	26-012297
8	book equity	us-gaap:StockholdersEquity	$693.1M	2025-12-31	2026-02-26	10-K	26-012297
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$158.5M	2025-12-31	2026-02-26	10-K	26-012297
10	total debt	us-gaap:LongTermDebt	$585.3M	2024-12-31	2026-02-26	10-K	26-012297
11	book equity	us-gaap:StockholdersEquity	$778.3M	2024-12-31	2026-02-26	10-K	26-012297
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$276.8M	2024-12-31	2026-02-26	10-K	26-012297
13	net income	us-gaap:NetIncomeLoss	$7.0M	2025-12-31	2026-02-26	10-K	26-012297
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$152.0M	2025-12-31	2026-02-26	10-K	26-012297
15	assets	us-gaap:Assets	$1.6B	2024-12-31	2026-02-26	10-K	26-012297
16	current assets	us-gaap:AssetsCurrent	$548.0M	2025-12-31	2026-02-26	10-K	26-012297
17	current liabilities	us-gaap:LiabilitiesCurrent	$120.6M	2025-12-31	2026-02-26	10-K	26-012297
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$199.3M	2025-12-31	2026-02-26	10-K	26-012297
19	liabilities	us-gaap:Liabilities	$571.8M	2025-12-31	2026-02-26	10-K	26-012297
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$91.0M	2025-12-31	2026-02-26	10-K	26-012297
21	operating income	us-gaap:OperatingIncomeLoss	$87.7M	2023-12-31	2026-02-26	10-K	26-012297
22	interest expense	us-gaap:InterestExpense	$20.3M	2023-12-31	2024-02-29	10-K	24-000030
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$675.0M	2023-12-31	2026-02-26	10-K	26-012297
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$666.8M	2022-12-31	2024-02-29	10-K	24-000030
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$541.5M	2021-12-31	2024-02-29	10-K	24-000030
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$15.3M	2025-12-31	2026-02-26	10-K	26-012297
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$189.4M	2024-12-31	2026-02-26	10-K	26-012297
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$10.6M	2024-12-31	2026-02-26	10-K	26-012297
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$154.6M	2023-12-31	2026-02-26	10-K	26-012297
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$15.2M	2023-12-31	2026-02-26	10-K	26-012297
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$145.3M	2022-12-31	2025-02-27	10-K	25-000041

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$30.1M	2022-12-31	2025-02-27	10-K	25-000041
33	current assets	us-gaap:AssetsCurrent	$745.1M	2024-12-31	2026-02-26	10-K	26-012297
34	current liabilities	us-gaap:LiabilitiesCurrent	$309.9M	2024-12-31	2026-02-26	10-K	26-012297
35	assets	us-gaap:Assets	$1.6B	2023-12-31	2025-02-27	10-K	25-000041
36	assets	us-gaap:Assets	$1.7B	2022-12-31	2024-02-29	10-K	24-000030
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,489,894	2026-02-23	2026-02-26	10-K	26-012297
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	46,276,241	2025-02-25	2025-02-27	10-K	25-000041

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.